ecancermedicalscience

Review

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives

7 Jan 2016
Romualdo Barroso-Sousa, Danilo Fonseca Reis Silva, Joao Victor Machado Alessi, Max Senna Mano

Luminal breast cancer, as defined by oestrogen and/or progesterone expression by immunohistochemistry, accounts for up to 75% of all breast cancers. In this population, endocrine therapy is likely to account for most of the gains obtained with the administration of adjuvant systemic treatment. The role of adjuvant chemotherapy in these patients remains debatable since it is known that only a small fraction of patients will derive meaningful benefit from this treatment whilst the majority will be exposed to significant and unnecessary chemotherapy-related toxicities, in particular the elderly and frail. Therefore, neoadjuvant endocrine therapy (NET) becomes an attractive option for selected patients with hormonal-receptor positive locally advanced breast cancer. In this review, we discuss the current role of NET and future perspectives in the field.

Related Articles

Priti Singh, Chaithanya Leon, Simran Kaur, Atul Batra, Prashant Tayade, Muthukrishnan Suriya Prakash, Ratna Sharma
Arunah Chandran, Ishu Kataria, Kunal Oswal, Rita Isaac, Meritxell Mallafré-Larrosa, Sathishrajaa Palaniraja, Rajaraman Swaminathan, Rohit Rebello, Nandimandalam Venkata Vani, Bindhya Vijayan, Moni Kuriakose, Arnie Purushotham, Rengaswamy Sankaranarayanan, Jerard Selvam, Richard Sullivan, Partha Basu
Chalothorn Wannaphut, Phuuwadith Wattanachayakul, Sakditad Saowapa, Ben Ponvilawan, Manasawee Tanariyakul, Jakrin Kewcharoen, Pitchaporn Yingchoncharoen, Thanathip Suenghataiphorn, Noppawit Aiumtrakul, Jared Acoba
Carl Arenos, Steven Lim, Andreu Lominoque, Isabela Reveldez, Angeli Sison-Dimaano, Nehar Pagandaman, Vincent Tatoy, Timothy Uy, Michael San Juan